Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma

Annals of Hematology

Volumn 84, Issue 8, 2005, Pages 517-525

  Glossmann, Jan Peter ^a   Staak, Jan Oliver ^a   Nogova, Lucia ^a   Diehl, Volker ^e   Scheid, Christoph ^a   Kisro, Jens ^b   Reis, Hans Edgar ^c   Peter, Norma ^d   Engert, Andreas ^a   Josting, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c St Franziskus Hospital Flensburg   (Germany)

^d Carl Thiem Hospital   (Germany)

^e German Hodgkin Study Group   (Germany)

Author keywords

Autologous tandem transplantation; Hodgkin's lymphoma; Non Hodgkin's lymphoma; Progressive disease; Refractory

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; PREDNISONE; PROCARBAZINE; RITUXIMAB; THIOTEPA; VINBLASTINE; VINCRISTINE; YTTRIUM 90;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOLOGOUS TANDEM TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HODGKIN DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROBABILITY; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE;

EID: 22344453188     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1011-y     Document Type: Article

References (33)

1. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group. Blood 96:1280-1286
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006 10.1056/NEJM199304083281404
3. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484
4. Glossmann JP, Josting A, Diehl V (2002) New treatments for Hodgkin's disease. Curr Treat Options Oncol 3:283-290
5. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051-1054
6. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545 10.1056/NEJM199512073332305
7. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A (2000) Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure? J Clin Oncol 18:332-339
8. Vose JM (1998) High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma. Ann Oncol 9 [Suppl 1]:S1-S3
9. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury. J Clin Oncol 17:423-429 1:STN:280:DyaK1MzosFCnsQ%3D%3D
10. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81:1137-1145
11. Josting A, Katay I, Rueffer U, Winter S, Tesch H, Engert A, Diehl V, Wickramanayake PD (1998) Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 9:289-295
12. Gribben JG, Linch DC, Singer CR, McMillan AK, Jarrett M, Goldstone AH (1989) Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73:340-344
13. Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, Scott JG, McCrae J, Murray C, Pantalony D et al (1993) High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant. J Clin Oncol 11:704-711
14. Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL, Packman CH, Eberly S, Sherman M, Tanner MA et al (1993) One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 11:2351-2361
15. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI (1998) Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens - a Southwest Oncology Group trial. J Clin Oncol 16:48-55
16. Ahmed T, Lake DE, Beer M, Feldman EJ, Preti RA, Seiter K, Helson L, Mittelman A, Kancherla R, Ascensao J, Akhtar T, Cook P, Goldberg R, Coleman M (1997) Single and double autotransplants for relapsing/ refractory Hodgkin's disease: Results of two consecutive trials. Bone Marrow Transplant 19:449-454
17. Bender JG, Unverzagt KL, Walker DE, Lee W, Van Epps DE, Smith DH, Stewart CC, To LB (1991) Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood 77:2591-2596
18. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
19. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita VT Jr (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210-218
20. Saez R, Dahlberg S, Appelbaum FR, Hartsock RJ, Lemaistre F, Coltman CA Jr, Fisher RI (1994) Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: A Southwest Oncology Group study. Hematol Oncol 12:75-85
21. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, Zanini M, Valagussa P, Bonadonna G (1997) Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15:528-534
22. Cabanillas F, Velasquez WS, McLaughlin P, Jagannath S, Hagemeister FB, Redman JR, Swan F, Rodriguez MA (1988) Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol 25:47-50
23. Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, Goldstone AH (1997) High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:745-752
24. Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, Dicke KA, Armitage JO (1993) High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients. Ann Oncol 4:767-773
25. Jones RJ, Piantadosi S, Mann RB, Ambinder RF, Seifter EJ, Vriesendorp HM, Abeloff MD, Burns WH, May WS, Rowley SD et al (1990) High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 8:527-537
26. Fitoussi O, Simon D, Brice P, Makke J, Scrobohaci ML, Bibi Triki T, Hennequin C, Ferme C, Gisselbrecht C (1999) Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 24:747-755
27. Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, Voilat L, Devidas A, Morschhauser F, Rohrlich P, Andre M, Lepage E, Ferme C (1999) Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group. Ann Oncol 10:1485-1488
28. Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ et al (1995) High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV+/-P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451-456
29. Gianni AM, Siena S, Bregni M, Lombardi F, Gandola L, Di Nicola M, Magni M, Peccatori F, Valagussa P, Bonadonna G (1993) High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease-a 6-year update. Ann Oncol 4:889-891
30. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, De Vol E, Ernst P (1992) Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 10:1690-1695
31. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14:1291-1296
32. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE et al (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin-s disease: the 21-year Seattle experience. J Clin Oncol 11:2342-2350
33. Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S, Chakraverty RK, Craddock C, Milligan DW, Pettengell R, Marsh JC, Linch DC, Goldstone AH, Williams CD, Mackinnon S (2002) Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 20:4022-4031